Angiotensin II-type 1 receptor interaction upregulates vascular endothelial growth factor messenger RNA levels in retinal pericytes through intracellular reactive oxygen species generation

Drugs under Experimental and Clinical Research

Volumn 29, Issue 2, 2003, Pages 75-80

  Yamagishi, Sho ichi ^a   Amano, S ^a   Inagaki, Y ^a   Okamoto, T ^a   Inoue, H ^a   Takeuchi, M ^b   Choei, H ^c   Sasaki, N ^c   Kikuchi, S ^d  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HOKURIKU UNIVERSITY   (Japan)

^c SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIOXIDANT; MESSENGER RNA; REACTIVE OXYGEN METABOLITE; TELMISARTAN; VASCULOTROPIN;

ANIMAL CELL; ARTICLE; CATTLE; CELL DAMAGE; CELL LOSS; CONTROLLED STUDY; DIABETIC RETINOPATHY; DNA SYNTHESIS; DOSE RESPONSE; DRUG EFFECT; NONHUMAN; PERICYTE; PROTEIN INTERACTION; RETINA; UPREGULATION;

ACETYLCYSTEINE; ANGIOTENSIN II; ANIMALS; ANTIOXIDANTS; CATTLE; CELLS, CULTURED; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; PERICYTES; REACTIVE OXYGEN SPECIES; RECEPTOR, ANGIOTENSIN, TYPE 1; RETINA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 0042027955     PISSN: 03786501     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Weiss D., Sorescu D., Taylor W.R. Angiotensin II and atherosclerosis. Am. J. Cardiol., 87, 25, 2001.
2. Naftilan A.J., Pratt R.E., Dzau V.J. Induction of platelet-derived growth factor A-chain and c-myc gene expressions by angiotensin II in cultured rat smooth muscle cells. J. Clin. Invest., 83, 1419, 1989
3. Ridker P.M., Gaboury C.L., Conlin P.R., Seely E.W., Williams G.H., Vaughan D.E. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II: Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation, 87, 1969, 1993.
4. Yamagishi S., Kobayashi K., Yamamoto H. Vascular pericytes not only regulate growth, but also preserve prostacyclin-producing ability and protect against lipid peroxide-induced injury of cocultured endothelial cells. Biochem. Biophys. Res. Commun., 190, 418, 1993.
5. Yamagishi S., Hsu C.C., Kobayashi K., Yamamoto H. Endothelin 1 mediates endothelial cell-dependent proliferation of vascular pericytes. Biochem. Biophys. Res. Commun., 191, 840, 1993.
6. Yamagishi S., Yonekura H., Yamamoto Y., et al. Vascular endothelial growth factor acts as a pericyte mitogen under hypoxic conditions. Lab. Invest., 79, 501, 1999.
7. Yamagishi S., Amano S., Inagaki Y., et al. Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes. Biochem. Biophys. Res. Commun., 290, 973, 2002.
8. Yamagishi S., Okamoto T., Amano S., et al. Palmitate-induced apoptosis of microvascular endothelial cells and pericytes. Mol. Med., 8, 178, 2002.
9. 2 analogue, protects against advanced glycation end products-induced injury in cultured retinal pericytes. Mol. Med., 8, 547, 2002.
10. Yamagishi S., Inagaki Y., Amano S., Okamoto T., Takeuchi M., Makita Z. Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product-induced injury through its anti-oxidative properties. Biochem. Biophys. Res. Commun., 296, 877, 2002.
11. Yamagishi S., Edelstein D., Du X.L., Kaneda Y., Guzmán M., Brownlee M. Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A. J. Biol. Chem., 276, 25096, 2001.
12. Yamagishi S., Inagaki Y., Okamoto T., Amano S., Koga K., Takeuchi M. Advanced glycation end products inhibit de novo protein synthesis and induce TGF-overexpression in proximal tubular cells. Kidney Int., 63, 464, 2003.
13. Yamagishi S., Yamamoto Y., Harada S., Hsu C.C., Yamamoto H. Advanced glycosylation end products stimulate the growth but inhibit the prostacyclin-producing ability of endothelial cells through interactions with their receptors. FEBS Lett., 384, 103, 1996.
14. Yamagishi S., Yonekura, H., Yamamoto, Y., et al. Advanced glycation end products-driven angiogenesis in vitro. Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. J. Biol. Chem., 272, 8723, 1997.
15. Yamagishi S., Fujimori H., Yonekura H., Yamamoto Y., Yamamoto H. Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells. Diabetologia, 41, 1435, 1998.
16. Yamagishi S., Inagaki Y., Amano S., et al. Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. J. Biol. Chem., 277, 20309, 2002.
17. Nomura M., Yamagishi S., Harada S., et al. Possible participation of autocrine and paracrine vascular endothelial growth factors in hypoxia-induced proliferation of endothelial cells and pericytes. J. Biol. Chem., 270, 28316, 1995.
18. Okamoto T., Yamagishi S., Inagaki Y., et al. Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J., 16, 1928, 2002.
19. Yamagishi S., Hsu C.C., Taniguchi M., et al. Receptor-mediated toxicity to pericytes of advanced glycosylation end products: A possible mechanism of pericyte loss in diabetic microangiopathy. Biochem. Biophys. Res. Commun., 213, 681, 1995.
20. Amano S., Yamagishi S., Kato N., et al. Sorbitol dehydrogenase overexpression potentiates glucose toxicity to cultured retinal pericytes. Biochem. Biophys. Res. Commun., 299, 183, 2002.
21. Adamis A.P., Miler J.W., Bernal M.T., et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am. J. Ophthalmol., 118, 445, 1994.
22. Aiello L.P., Avery R.L., Arrigg P.G., et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med., 331, 1480, 1994.
23. Murata T., Ishibashi T., Khalil A., Hata Y., Yoshikawa H., Inomata H. Vascular endothelial growth factor plays a role in hyperpermeability of diabetic retinal vessels. Ophthalmic Res., 27, 48, 1995.
24. Segawa Y., Shirao Y., Yamagishi S., et al. Upregulation of retinal vascular endothelial growth factor mRNAs in spontaneously diabetic rats without ophthalmoscopic retinopathy. Ophthalmic. Res., 30, 333, 1998.
25. Funatsu H., Yamashita H., Nakanishi Y., Hori S. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. Br. J. Ophthalmol., 86, 311, 2002.
26. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. BMJ, 317, 703, 1998.
27. Chaturvedi N., Sjolie A.K., Stephenson J.M., et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet, 351, 28, 1998.